Clinical trial
Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of…
NCT00378911 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00378911 |
|---|---|
| Title | Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus |
| Official title | A Phase II Evaluation of Sunitinib Malate (Sutent®, SU11248, NCI-Supplied Agent , NSC # 736511) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Collaborators | Gynecologic Oncology Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Uterine Sarcoma, Uterine Leiomyosarcoma |
| Intervention type | Drug |
| Interventions | sunitinib malate |
| Enrollment | 44 |
| Start date | Oct 1, 2006 |
| Primary completion | Jun 1, 2007 |
| Completion | Jan 1, 2010 |
| First posted | Sep 21, 2006 |
| Last update posted | Jul 23, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: